NTHI
NeOnc Technologies Holdings, Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$108.31M
P/E Ratio
—
EPS
$-3.20
Beta
—
52W High
$12.99
52W Low
$3.20
50-Day MA
$7.34
200-Day MA
$8.21
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About NeOnc Technologies Holdings, Inc. Common Stock
NeOnc Technologies Holdings, Inc. is a forward-thinking biotechnology firm dedicated to revolutionizing cancer treatment through advanced immunotherapy and molecular medicine. With a strong pipeline of innovative product candidates targeting crucial unmet needs in oncology, the company is strategically positioned to reshape treatment paradigms and enhance patient outcomes. Its collaborative partnerships within the biopharmaceutical arena further bolster its capabilities in bringing therapeutic innovations to market, rendering NeOnc a compelling investment prospect within the burgeoning cancer therapeutics sector.
Fundamentals
| Revenue (TTM) | 39,990 |
| Gross Profit (TTM) | 39,990 |
| EBITDA | — |
| Operating Margin | -145638.00% |
| Return on Equity | 0.00% |
| Return on Assets | -1167.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.80 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | 2708.52 |
| EV/Revenue | 2846.04 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $25.19M |
| Float | $9.36M |
| % Insiders | 58.52% |
| % Institutions | 8.55% |
Historical Volatility
HV 10-Day
54.51%
HV 20-Day
72.01%
HV 30-Day
74.27%
HV 60-Day
76.78%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($15.00 target)
Data last updated: 4/30/2026